NACDS New Products In Brief
Bayer launches non-fizz Alka-Seltzer: Bayer HealthCare launches July 15 Alka-Seltzer Plus Fast Crystal Packs, a "taste-free, fizz-free powder that transforms many beverages, such as juice, tea and water, into powerful cold medicine," according to Allyson Daly, senior manager of the firm's global public relations and internal communication. Bayer showcased the product, along with others, at the National Association of Chain Drug Stores' Marketplace trade show in June (1"The Tan Sheet" July 13, 2009). The products are available in 10-count packages with a suggested retail price between $5.59 and $7.29 in most major retailers and in 4-count packages in select retailers for $2.99. Advertising includes television and nationwide sampling in stores and other venues
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.
Center for Biologics Evaluation and Research Director Vinay Prasad said Commissioner Martin Makary wants to release previously inaccessible FDA documents, but previous commissioners have made the same pronouncements only to make little progress.
The Pediatric Advisory Committee will review postmarketing safety for three vaccines and the oncologic drugs panel will consider the return of GSK’s belantamab mafodotin. An FDA notice about a 30 July meeting on Capricor’s deramiocel for Duchenne muscular dystrophy was withdrawn.